ACTAVIA LIFE SCIENCES, INC.: 10-K filed 2024-01-05

Name: ACTAVIA LIFE SCIENCES, INC.: 10-K filed 2024-01-05
Creator: ACTAVIA LIFE SCIENCES, INC.

What ACTAVIA LIFE SCIENCES, INC. reported in its annual report filed 2024-01-05 (fiscal FY 2023): 25 published measures, 51 facts as tagged in accession 0001213900-24-001370.

This filing

Form: 10-K (annual report)
Filed: 2024-01-05
Fiscal period: fiscal FY 2023
Accession: 0001213900-24-001370 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ACTAVIA LIFE SCIENCES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-09-30	95,657	USD
At 2022-09-30	85,276	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-09-30	2,051,566	USD
At 2022-09-30	1,773,873	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-09-30	-1,955,909	USD
At 2022-09-30	-1,688,597	USD
At 2021-09-30	-2,753,812	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	-4,442,535	USD	365
2021-10-01 to 2022-09-30	-686,588	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	-8,516	USD	365
2021-10-01 to 2022-09-30	-312,663	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	44,139	USD	365
2021-10-01 to 2022-09-30	341,178	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-09-30	-28,663,602	USD
At 2022-09-30	-24,221,067	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	578,016,591	shares	365
2021-10-01 to 2022-09-30	111,425,950	shares	365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	578,016,591	shares	365
2021-10-01 to 2022-09-30	111,425,950	shares	365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	-0.01	USD/shares	365
2021-10-01 to 2022-09-30	-0.01	USD/shares	365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	-0.01	USD/shares	365
2021-10-01 to 2022-09-30	-0.01	USD/shares	365

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	3,858,793	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	-4,238,414	USD	365
2021-10-01 to 2022-09-30	141,088	USD	365

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	1,107	USD	365
2021-10-01 to 2022-09-30	2,464	USD	365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-09-30	2,051,566	USD
At 2022-09-30	1,681,906	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2023-09-30	959,659	USD
At 2022-09-30	822,127	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	4,238,414	USD	365
2021-10-01 to 2022-09-30	-141,088	USD	365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	92,247	USD	365
2021-10-01 to 2022-09-30	83,842	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-09-30	771,811,360	shares
At 2022-09-30	179,979,361	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2023-09-30	74,986	USD
At 2022-09-30	39,363	USD
At 2021-09-30	10,848	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2023-09-30	25,935,882	USD
At 2022-09-30	22,352,491	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2023-09-30	498,557	USD
At 2022-09-30	529,193	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2023-09-30	20,671	USD
At 2022-09-30	45,913	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	287,374	USD	365
2021-10-01 to 2022-09-30	300,070	USD	365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	-204,121	USD	365
2021-10-01 to 2022-09-30	-827,676	USD	365

Inspect the source

Entity: ACTAVIA LIFE SCIENCES, INC. / CIK 0001582249
Captured: 2026-09-22 19:52 UTC
SEC response SHA-256: 1fa3da8551fa6523f67ea25c9d27ef0c331ae8c1fcbc6eda23b86adc30a6f71c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001582249.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))